WO2022262828A8 - 抗il-36r抗体及其用途 - Google Patents

抗il-36r抗体及其用途 Download PDF

Info

Publication number
WO2022262828A8
WO2022262828A8 PCT/CN2022/099294 CN2022099294W WO2022262828A8 WO 2022262828 A8 WO2022262828 A8 WO 2022262828A8 CN 2022099294 W CN2022099294 W CN 2022099294W WO 2022262828 A8 WO2022262828 A8 WO 2022262828A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
binding fragment
binding
chimeric
Prior art date
Application number
PCT/CN2022/099294
Other languages
English (en)
French (fr)
Other versions
WO2022262828A1 (zh
Inventor
龙西
徐宏江
施伟
王亮亮
陆臻桢
Original Assignee
正大天晴药业集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正大天晴药业集团股份有限公司 filed Critical 正大天晴药业集团股份有限公司
Priority to CA3221648A priority Critical patent/CA3221648A1/en
Priority to CN202280041588.8A priority patent/CN117480183A/zh
Priority to EP22824301.0A priority patent/EP4357361A1/en
Priority to AU2022291974A priority patent/AU2022291974A1/en
Priority to KR1020247000680A priority patent/KR20240022546A/ko
Priority to BR112023026429A priority patent/BR112023026429A2/pt
Priority to IL308884A priority patent/IL308884A/en
Publication of WO2022262828A1 publication Critical patent/WO2022262828A1/zh
Publication of WO2022262828A8 publication Critical patent/WO2022262828A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

提供了抗IL-36R抗体及其用途，具体而言，提供了结合IL-36R的小鼠、嵌合或人源化抗体或其抗原结合片段，还提供了编码所述抗体或其抗原结合片段的核酸分子，以及用于表达所述抗体或其抗原结合片段的表达载体和宿主细胞。此外，还提供了所述抗体或其抗原结合片段的制备方法和使用方法，包括治疗和预防IL-36/IL-36R介导的相关疾病和病症。
PCT/CN2022/099294 2021-06-18 2022-06-17 抗il-36r抗体及其用途 WO2022262828A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3221648A CA3221648A1 (en) 2021-06-18 2022-06-17 Anti-il-36r antibody and use thereof
CN202280041588.8A CN117480183A (zh) 2021-06-18 2022-06-17 抗il-36r抗体及其用途
EP22824301.0A EP4357361A1 (en) 2021-06-18 2022-06-17 Anti-il-36r antibody and use thereof
AU2022291974A AU2022291974A1 (en) 2021-06-18 2022-06-17 Anti-il-36r antibody and use thereof
KR1020247000680A KR20240022546A (ko) 2021-06-18 2022-06-17 항il-36r 항체 및 그의 사용
BR112023026429A BR112023026429A2 (pt) 2021-06-18 2022-06-17 Anticorpo anti-il-36r isolado ou um fragmento de ligação ao antígeno deste, imunoconjugado ou molécula multiespecífica, composição farmacêutica, método para inibir a transdução de sinal de il-36/il-36r e método para tratar doenças e condições relacionadas mediadas por il-36/il-36r em um sujeito em necessidade
IL308884A IL308884A (en) 2021-06-18 2022-06-17 Anti-IL-36R antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110675925.6 2021-06-18
CN202110675925 2021-06-18

Publications (2)

Publication Number Publication Date
WO2022262828A1 WO2022262828A1 (zh) 2022-12-22
WO2022262828A8 true WO2022262828A8 (zh) 2023-11-16

Family

ID=84526886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/099294 WO2022262828A1 (zh) 2021-06-18 2022-06-17 抗il-36r抗体及其用途

Country Status (9)

Country Link
EP (1) EP4357361A1 (zh)
KR (1) KR20240022546A (zh)
CN (1) CN117480183A (zh)
AU (1) AU2022291974A1 (zh)
BR (1) BR112023026429A2 (zh)
CA (1) CA3221648A1 (zh)
IL (1) IL308884A (zh)
TW (1) TW202317626A (zh)
WO (1) WO2022262828A1 (zh)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US9023995B2 (en) * 2011-11-16 2015-05-05 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
WO2020018503A2 (en) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies

Also Published As

Publication number Publication date
EP4357361A1 (en) 2024-04-24
KR20240022546A (ko) 2024-02-20
TW202317626A (zh) 2023-05-01
BR112023026429A2 (pt) 2024-03-05
WO2022262828A1 (zh) 2022-12-22
CN117480183A (zh) 2024-01-30
AU2022291974A1 (en) 2024-01-25
IL308884A (en) 2024-01-01
CA3221648A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
WO2019224025A3 (en) Antagonizing cd73 antibody
MY193112A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
AU2017297138A8 (en) Anti-PD-1 antibodies, method for producing same and method for using same
ZA202100676B (en) Anti-tigit antibody and uses thereof
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2009028663A1 (ja) 抗Claudin-3抗体
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MX2022011951A (es) Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
WO2017014679A3 (en) Humanized monoclonal antibody specific to syndecan-1
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
EA202193351A1 (ru) Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
WO2018088877A3 (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
SA519401032B1 (ar) (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
MX2022000586A (es) Anticuerpos anti-tigit y aplicacion de los mismos.
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22824301

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 308884

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3221648

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023576236

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/015283

Country of ref document: MX

Ref document number: P6003257/2023

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 2301008217

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 523451943

Country of ref document: SA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023026429

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202393447

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20247000680

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247000680

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2022291974

Country of ref document: AU

Ref document number: 807249

Country of ref document: NZ

Ref document number: AU2022291974

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2022824301

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022291974

Country of ref document: AU

Date of ref document: 20220617

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022824301

Country of ref document: EP

Effective date: 20240118

ENP Entry into the national phase

Ref document number: 112023026429

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20231214